LGND Ligand Pharmaceuticals PE ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: LGND
- PE Ratio
The current PE ratio of LGND can't be determined, as the TTM EPS of -$7.2 is negative. The last PE ratio of Ligand Pharmaceuticals, recorded in September 2024, was 37.91.
LGND PE ratio history
The PE ratio of Ligand Pharmaceuticals has averaged 85.6 over the last ten years. Over the past ten years, LGND's PE ratio was at its highest in the Sep 2020 quarter at 794.33, when the stock price was $95.32 and the EPS was $0.12. The lowest value was in the Dec 2019 quarter, when it reached 3.15 with a price of $104.29 and an EPS of $33.13.
Ligand Pharmaceuticals PE ratio history chart
Ligand Pharmaceuticals PE ratio by year
Maximum annual decrease: -91.22% in 2018
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2024 | N/A | N/A | $107.15 | -$0.22 |
| 2023 | 23.65 | N/A | $71.42 | $3.02 |
| 2022 | N/A | N/A | $66.8 | -$1.98 |
| 2021 | 44.9 | N/A | $154.46 | $3.44 |
| 2020 | N/A | N/A | $99.45 | -$0.18 |
| 2019 | 3.15 | -84.28% | $104.29 | $33.13 |
| 2018 | 20.04 | -91.22% | $135.7 | $6.77 |
| 2017 | 228.22 | N/A | $136.93 | $0.6 |
| 2016 | N/A | N/A | $101.61 | -$0.08 |
| 2015 | 9.34 | -89.64% | $108.42 | $11.61 |
| 2014 | 90.19 | -3.98% | $53.21 | $0.59 |
| 2013 | 93.93 | N/A | $52.6 | $0.56 |
| 2012 | N/A | N/A | $20.74 | -$0.03 |
| 2011 | 24.22 | N/A | $11.87 | $0.49 |
| 2010 | N/A | N/A | $8.92 | -$0.53 |
Ligand Pharmaceuticals PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Mar 2025 | N/A | N/A | $105.14 | -$7.2 |
| Dec 2024 | N/A | N/A | $107.15 | -$0.22 |
| Sep 2024 | 37.91 | 9.79% | $100.09 | $2.64 |
| Jun 2024 | 34.53 | 157.49% | $84.26 | $2.44 |
| Mar 2024 | 13.41 | -43.3% | $73.1 | $5.45 |
| Dec 2023 | 23.65 | -62.11% | $71.42 | $3.02 |
| Sep 2023 | 62.42 | 35.93% | $59.92 | $0.96 |
| Jun 2023 | 45.92 | -13.23% | $72.1 | $1.57 |
| Mar 2023 | 52.92 | N/A | $73.56 | $1.39 |
| Dec 2022 | N/A | N/A | $66.8 | -$1.98 |
| Sep 2022 | N/A | N/A | $86.11 | -$1.27 |
| Jun 2022 | N/A | N/A | $89.22 | -$0.47 |
| Mar 2022 | 79.22 | 76.44% | $112.49 | $1.42 |
| Dec 2021 | 44.9 | 32.76% | $154.46 | $3.44 |
| Sep 2021 | 33.82 | -25.75% | $139.32 | $4.12 |
LGND Price vs fair value
You can ether set your own Fair P/E multiple or use one of the automatically calculated Fair P/E multiples.
Fair P/E calculation
PE Ratio is an attempt to estimate a fair PE ratio of a stock based on its earnings and growth rate.
This formula is a modified version of the classic Graham-Dodd Formula (V= EPS x (8.5+2g)), originally developed by Benjamin Graham, to calculate the fair price of a stock based on its earnings and growth rate.
The formula we have created is an adaptation of this approach, designed to maintain a balance between simplicity and growth sensitivity.
It is calculated using the following formula:
IF g < 5: Fair PE = b
IF g >= 5: Fair PE = m × g
Here’s what each part of the formula means:
g: Growth is calculated as the average of the three-year average EPS growth rate and the one-year EPS growth rate (annually). This approach provides a balanced measure of growth by factoring in both the long-term growth trend and the most recent annual growth performance. If one of the growth metrics is not available, the remaining metric is used to determine growth. The fair P/E value is capped at 100 to prevent distortions caused by extreme EPS growth rates, such as those resulting from large percentage increases from a low base.
m: This is the long term historical median PEG (Price/Earnings to Growth) ratio of the overall market. It serves as a benchmark, adjusting the Fair PE based on typical market conditions.
b: Base PE (static value set to 8). If the company's growth rate is less than 5, the Fair PE is set at a conservative baseline of 8. This is because declining companies generally deserve a lower PE ratio.
Fixed vs Dynamic
Fixed: The Fair PE ratio for all data points is calculated using a single, constant average EPS growth rate, determined based on the most recent period. This means that the same growth rate is applied to all historical data points. Dynamic: The Fair PE ratio for each historical data point is calculated using the trailing average EPS growth rate specific to that point in time. This means that for each data point, the corresponding trailing EPS growth rate is used, ensuring that the Fair PE ratio reflects the growth conditions that were relevant at that specific point in history.
LGND average PE ratio chart
PE vs average
LGND PE vs peers
| Stock name | PE ratio | Market cap |
|---|---|---|
| MRK Merck & Co Inc | 11.44 | $197.88B |
| PFE Pfizer Inc | 16.82 | $132.92B |
| JNJ Johnson & Johnson | 17.08 | $372.22B |
| BMY Bristol Myers Squibb Co | 18.03 | $98.31B |
| AMGN Amgen Inc | 26.25 | $155.97B |
| LLY ELI LILLY & Co | 62.29 | $728.43B |
| BAX Baxter International Inc | N/A | $15.42B |
| LGND Ligand Pharmaceuticals Inc | N/A | $2.04B |
- Market
- Price
- Valuation
- Dividend
- Earnings
- Per share
- Balance sheet
- Liquidity
- Margins
- Efficiency
- Growth
- Market
- Price
- Valuation
- Dividend
- Earnings
- Per share
- Balance sheet
- Liquidity
- Margins
- Efficiency
- Growth
- Market
- Price
- Valuation
- Dividend
- Earnings
- Per share
- Balance sheet
- Liquidity
- Margins
- Efficiency
- Growth
Frequently asked questions
What is Ligand Pharmaceuticals's PE ratio?
The current price to earnings ratio of LGND can't be calculated, as its EPS of -$7.2 is negative.
What is the 3-year average PE ratio for Ligand Pharmaceuticals (LGND)?
The 3-year average PE ratio for LGND stock is 38.68.
What is the 5-year average PE ratio for Ligand Pharmaceuticals (LGND)?
The 5-year average PE ratio for LGND stock is 102.43.
What is the highest PE ratio for LGND?
The highest quarterly PE ratio in the last ten years has been 794.33 and it was in the Sep 2020 quarter.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.